Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Daridorexant

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Daridorexant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 49,323Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nxera Pharma's QUVIVIQ Approved In Japan For Insomnia
    Nxera Pharma's QUVIVIQ Approved In Japan For Insomnia

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2951862/0/en/Nxera-Pharma-Receives-Approval-of-QUVIVIQ-daridorexant-25-and-50-mg-in-Japan-for-the-Treatment-of-Insomnia.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    New data with daridorexant to be presented at SLEEP 2024
    New data with daridorexant to be presented at SLEEP 2024

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2891892/0/en/New-data-with-daridorexant-to-be-presented-at-SLEEP-2024.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Sosei Announces Submission of New Drug Application in Japan for Daridorexant
    Sosei Announces Submission of New Drug Application in Japan for Daridorexant

    31 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/31/2769844/0/en/Sosei-Heptares-Announces-Submission-of-New-Drug-Application-in-Japan-for-Daridorexant-ACT-541468-a-Dual-Orexin-Receptor-Antagonist-for-the-Treatment-of-Insomnia.html

    GLOBENEWSWIRE
    31 Oct 2023
    Share Share
    Idorsia announces its insomnia medication, QUVIVIQ, is now covered by CVS
    Idorsia announces its insomnia medication, QUVIVIQ, is now covered by CVS

    10 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/idorsia-announces-its-insomnia-medication-quviviq-daridorexant-is-now-covered-by-cvs-301872158.html

    PR NEWSWIRE
    10 Jul 2023
    Share Share
    Idorsia launches QUVIVIQ (daridorexant) in Switzerland
    Idorsia launches QUVIVIQ (daridorexant) in Switzerland

    12 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/12/2685940/0/en/Idorsia-launches-QUVIVIQ-daridorexant-in-Switzerland-a-first-in-class-treatment-for-chronic-insomnia-disorder-to-improve-both-nighttime-symptoms-and-daytime-functioning.html

    GLOBENEWSWIRE
    12 Jun 2023
    Share Share
    Idorsia notes potential $440.8M Asia licensing deal to extend cash runway
    Idorsia notes potential $440.8M Asia licensing deal to extend cash runway

    06 Jun 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/idorsia-announces-few-details-on-potential-440-8m-asia-licensing-deal/

    Katherine Lewin ENDPTS
    06 Jun 2023
    Share Share